Latest Regulatory News

Jervois Global Limited has initiated a prepackaged Chapter 11 recapitalisation process in the US, leading to the suspension of its shares on multiple exchanges. Shareholders are being notified with detailed documentation as the company seeks to restructure its finances.

Riversgold Limited reports compelling high-grade assay results from its Saint John Project in New Brunswick, Canada, confirming significant multi-metal mineralisation and securing drilling approval for 2025.

Close the Loop Limited has ended acquisition discussions with Adamantem Capital but remains confident in its standalone growth strategy, projecting steady revenue and an EBITDA range of $11m-$13m for the first half of 2025.

Bio-Gene Technology Limited has been awarded two U.S. Department of Defense grants totaling A$3 million to develop innovative insect control products targeting military and civilian markets.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

Infinity Lithium reports steady progress on its San José Lithium Project with updated mining licence requirements and a strategic pivot to new European funding opportunities.

BCI Minerals reports robust progress in its Mardie Salt and Potash Project, achieving financial close on a $981 million debt facility and advancing construction beyond the halfway mark. The company maintains a strong focus on sustainability and safety as it targets first salt shipment in Q2 FY27.

White Cliff Minerals has secured all necessary permits to initiate drilling at its Rae Copper Project in Nunavut, targeting exceptionally high-grade copper zones identified in 2024. Drilling is set to commence in March 2025, focusing on the Hulk and Danvers prospects.

Holista Colltech Limited reports a notable financial recovery in 4QFY24, underpinned by strong cash inflows and a rebound in its Food Ingredients division, alongside a leadership change aimed at steering future growth.

CurveBeam AI Limited reported a remarkable 150% increase in device purchase orders in Q2 FY25, driven by strong demand for its HiRise™M platform and a new commercial agreement with Stryker. The company is advancing validation of its Enhanced HiRise™ for robotic surgical systems, despite a regulatory delay for its BMD SaaS module.

Algorae Pharmaceuticals reports robust progress in its drug development pipeline, highlighted by promising preclinical results for cardiovascular and dementia candidates and significant AI platform enhancements.

CurveBeam AI has reported a record quarter for HiRise™ device purchase orders, driven by a strategic expansion with Stryker in Australia and New Zealand. The company also advanced its FDA regulatory pathway for its BMD module, setting sights on mid-2025 submission.